论文部分内容阅读
目的:探讨双水平式呼吸道正压通气(BiPAP)联合重组人脑利钠肽(rhBNP)在重症急性心力衰竭抢救治疗中的作用。方法:以我院2011年2月-2014年8月期间所收88例重症急性心力衰竭患者展开研究,分为两组,各44例。对照组采取常规治疗及BiPAP,观察组在对照组基础上应用rhBNP,比较两组呼吸机撤机时间、24小时平均尿量、用药0.5与24h临床症状好转率及抢救有效率。结果:观察组的0.5h、24h症状好转率56.8%、86.4%、均好于对照组的34.1%、63.6%(P<0.05)。观察组患者的撤机时间、24h平均尿量均高于对照组(P<0.05):观察组患者抢救总有效率为93.2%,高于对照组的72.7%(P<0.05)。结论:BiPAP联合rhBNP在抢救重症急性心力衰竭患者可迅速缓解心衰症状、发挥利尿作用,提高抢救有效率。
Objective: To investigate the effect of bi-level positive airway pressure (BiPAP) combined with recombinant human brain natriuretic peptide (rhBNP) in the treatment of severe acute heart failure. Methods: A total of 88 patients with severe acute heart failure admitted to our hospital from February 2011 to August 2014 were divided into two groups (44 in each). The control group was given routine treatment and BiPAP. The observation group was given rhBNP on the basis of the control group. The ventilatory machine weaning time, the average 24-hour urine output, the improvement rate of clinical symptoms and the rescue and rescue efficiency at 0.5 and 24 hours were compared between the two groups. Results: The symptom improvement rate in observation group was 56.8% and 86.4% at 0.5h and 24h, respectively, which were significantly better than those in control group (34.1% and 63.6%, P <0.05). The weaning time and average urine output of 24h in observation group were higher than those in control group (P <0.05). The total effective rate of observation group was 93.2%, which was higher than that of control group (72.7%, P <0.05). Conclusion: BiPAP combined with rhBNP can relieve the symptoms of heart failure, relieve diuresis and improve the efficiency of rescue in patients with severe acute heart failure.